Effect of Rosiglitazone

Assessment of the Effect of Rosiglitazone on Insulin Secretion in Healthy Volunteers

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00285142

Enrollment

Registered

2006-02-01

Start date

2004-06-30

Completion date

2004-11-30

Last updated

2019-06-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

rosiglitazone, insulin secretion, clinical trial, healthy, persons

Brief summary

To evaluate : * acute effects of a single dose of 8 mg rosiglitazone (therapeutic dose) * on insulin secretion and * insulin sensitivity in 12 healthy male subjects.

Interventions

DRUGrosiglitazone

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

MALE

Age

18 Years to 35 Years

Healthy volunteers

Yes

Inclusion criteria

* BMI between 18.0 and 24.0

Exclusion criteria

Design outcomes

Primary

Measure	Time frame
insulin response and insulin sensitivity assessed by 2-hours 10 mmol/l hyperglycemic clamp, started 45 min after treatment intake	—

Secondary

Measure	Time frame
insulin clearance	—
basal glycemia and insulinemia	—
tolerance	—

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026